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Cerebral Ischemia Detected with
Diffusion-Weighted MR Imaging after
Protected Carotid Artery Stenting:
Comparison of Distal Balloon and Filter
Device
Objective: The aim of this study was to examine the incidence of ischemia dur-
ing protected carotid artery stenting (CAS) as well as to compare the protective
efficacy of the balloon and filter devices on diffusion-weighted MR imaging (DWI).
Materials and Methods: Seventy-one consecutive protected CAS procedures
in 70 patients with a severe (> 70%) or symptomatic moderate (> 50%) carotid
artery stenosis were examined. A balloon device (PercuSurge GuardWire) and a
filter device (FilterWire EX/EZ, Emboshield) was used in 33 cases (CAS-B group)
and 38 cases (CAS-F group) to prevent distal embolization, respectively. All the
patients underwent DWI within seven days before and after the procedures. The
number of new cerebral ischemic lesions on the post-procedural DWI were count-
ed and divided into ipsilateral and contralateral lesions according to the relation-
ship with the stenting side.
Results: New cerebral ischemic lesions were detected in 13 (39.4%) out of the
33 CAS-Bs and in 15 (39.5%) out of the 38 CAS-Fs. The mean number of total,
ipsilateral and contralateral new cerebral ischemic lesion was 2.39, 1.67 and 0.73
in the CAS-B group and 2.11, 1.32 and 0.79 in the CAS-F group, respectively. No
statistical differences were found between the two groups (p = 0.96, 0.74 and
0.65, respectively). The embolic complications encountered included two retinal
infarctions and one hemiparesis in the CAS-B group (9.09%), and one retinal
infarction, one hemiparesis and one ataxia in the CAS-F group (7.89%). There
was a similar incidence of embolic complications in the two groups (p = 1.00). 
Conclusion: The type of distal protection device used such as a balloon and fil-
ter does not affect the incidence of cerebral embolization after protected CAS. 
arotid artery stenting (CAS) is a comparative method for treating a carotid
artery stenosis. However, the occurrence of distal embolization with the
procedure is still a major concern because friable plaque can be separated
from the diseased vessel wall during the procedure. Therefore, several protection
devices have been developed and applied to the prevention of a distal embolization.
The use of filter devices by interventional neuroradiologists has increased recently to
the point that their use has exceeded that of balloon devices due to technical
convenience of the former. However, safety of the two different protection devices has
not been fully tested. Therefore, the use of the filter device is not justified.
Diffusion-weighted MR imaging (DWI) is very sensitive and specific technique for
diagnosing cerebral ischemia (1 3). DWI is widely accepted as a marker of ischemic
complications in many interventional and surgical procedures (1, 4 11). Hammer et
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Cal. examined the incidence of new DWI lesions after
protected CAS with two types of distal filter devices (12).
In that study, new focal ischemic lesions were detected on
DWI in 40% of the procedures. Ninety percent of these
events were clinically silent and 62% occurred outside the
vascular territory of the treated side. Du Mesnil de
Rochemont et al. also detected new DWI lesions in 14
(28%) out of 50 cases in the territory of the stented
internal carotid artery and in seven (14%) out of 50 cases
in other vascular territories after protected CAS with a
distal filter device (13). Asakura et al. used DWI to
compare the two types of embolic protection methods
during CAS, and reported better protection with a simulta-
neous double occlusion of both the internal and external
carotid arteries than with the single protection of the
internal carotid artery (ischemic spots on DWI; 36.0% vs.
55.0%, respectively) (14). Asakura et al. also
demonstrated excellent protection using a flow reversal
device (Parodi Anti-Emboli System) during CAS by DWI
(ischemic spots on DWI; 18.2%) (15). However, there has
been no comparison of the number of new DWI lesions
formed after protected CAS using the distal balloon with
that using the filter device.
In this study, the occurrence of cerebral embolization
after protected CAS in a balloon device group (CAS-B)
and a filter device group (CAS-F) was examined and
compared using DWI. 
MATERIALS AND METHODS
Data Collection
From May 2002 to October 2005, 73 protected CASs
were performed in 72 patients with a severe (> 70%) or
symptomatic moderate (> 50%) carotid artery stenosis
using a distal balloon or a filter device prior to the deploy-
ment of the stent. Among these patients, two patients, who
had undergone CAS-B, were excluded due to intolerance
that developed while inflating the balloon device. The
remaining 70 patients consisted of 59 males and 11 females
with a mean age of 66.5 years (age range: 43 to 84 years).
Among the 71 CAS procedures, 35 and 36 CAS
procedures were performed in the right and left carotid
artery, respectively. Bilateral CAS was performed in one
patient with a 15-month interval. Four types of self-
expandable stents were used. The SMART (Cordis Corp,
Miami, FL), PRECISETM RX (Cordis Corp., Miami, FL),
Carotid WALLSTENTTM  MonorailTM (Boston Scientific
Corp., Galway, Ireland), and Zilver 518 (William COOK
Europe ApS, Bjaeverskov, Denmark) stents were used in
28, 25, 17 and one procedures, respectively. During the
early period from May 2002 to February 2004, one type of
balloon device, the PercuSerge GuardWire system
(Medtronic, Danvers, MA) was used in 33 procedures
(CAS-B), and three kinds of filter device, the FilterWire
EXTM (Boston Scientific Corp, Natick, MA), FilterWire
EZTM (Boston scientific Corp., Natick, MA), and
Emboshield filter protection systems (MedNova, Galway,
Ireland), were used in seven, 23 and eight procedures
during late period from March 2004 to October 2005,
respectively (CAS-F). 
One of three experienced interventional neuroradiolo-
gists performed the procedures. DWI was obtained from all
patients within one week before the procedures and
between 24 hours to one week after the procedures. Two
neuroradiologists counted and recorded the number of
new high signal intensities (HI) in the cerebral hemispheres
by comparing the pre- and post-procedural DWIs for each
CAS procedure without any knowledge of the clinical
status of the patients or the types of protection devices
used. The new HIs were divided into the ipsilateral or
contralateral type according to the relationship with the
treated side. The following information for each patient
was also collected: age, gender, degree of ipsilateral and
contralateral carotid artery stenosis, presenting symptoms,
HbA1c value in the patients with diabetes mellitus, ulcera-
tion (presence of contrast or hazy contour beyond the
vessel lumen) of the carotid artery stenosis on the baseline
angiogram and any change in the neurological status at the
time of DWI acquisition. The degree of carotid artery
stenosis was calculated based on the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
criteria.
Although not established, some risk factors have been
suggested as a predictor of complications after CAS (13,
16 30). Therefore, the following variables, which were
used to create a risk score for peri-interventional complica-
tions after CAS, were defined as risk factors in this study
(30): diabetes mellitus with inadequate glycemic control
(HbA1c > 7%), age  80 years, ulceration of the carotid
artery stenosis and a contralateral stenosis  50%.
Written informed consent was obtained from all the
patients before the procedure.
Statistics
The difference in the number of new cerebral ischemic
lesions between the two groups was evaluated using a
Mann-Whitney test. The incidence of clinically apparent
neurological complications in the two groups was
compared using a Pearson’s 
2 test. In addition, variables
such as age and the degree of the ipsilateral and contralat-
eral carotid artery stenosis in the two groups were
compared using an independent t-test or Mann-Whitney
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Pearson’s 
2 test. The difference in the number of new
cerebral ischemic lesions according to the three type of
filter devices used was compared using a Kruskal Wallis
test. For all the tests in this study, p values < 0.05 were
considered significant. All the statistical analyses were
performed using the SPSS software program (SPSS 10.0;
SPSS, Chicago, IL).
Carotid Artery Stenting Procedure
All the patients were administered clopidogrel (75
mg/day) and aspirin (100 mg/day) at least 72 hours before
the CAS procedure. An 8 or 9 Fr sheath (Cook Inc.,
Bloomington, IN) was inserted into the common femoral
artery for vascular access, and a 6 Fr sheath (Cook Inc.,
Bloomington, IN), as temporary cardiac pacemaker, was
inserted into the common femoral vein. Intravenous
heparin (80 IU/Kg) was injected as a bolus and then
dripped continuously during the procedure to maintain a
two or three times elongated activated clotting time. A 5
Fr neuroangiographic catheter was introduced into the
target lesion-related common carotid artery, and a 300-cm
0.035/0.038-inch exchange guidewire (Terumo Corp.,
Tokyo, Japan) was advanced into the external carotid
artery. The 5 Fr neuroangiographic catheter was then
replaced with either a 7 Fr carotid sheath (Shuttle Flexor;
Cook Inc., Bloomington, IN) or an 8 Fr guiding catheter
(VistaBrite tip; Cordis Corp., Miami, FL). The appropriate
length and diameter stent was determined according to the
degree and length of the stenotic segment and the diameter
of carotid artery immediately below the bifurcation
measured on the baseline angiogram. After passing
through the stenotic segment, a balloon or filter type distal
protection device was deployed in the distal cervical or
proximal petrosal internal carotid artery. The stenotic
lesions were pre-dilated with a 3- or 4-mm diameter
balloon catheter (Symmetry/Ultra-soft SV; Boston
Scientific Corp., Natick, MA, or Amiia/Savvy; Cordis
Europa N.V., Roden, Netherlands), with the exception of
14 cases. After this or as a primary dilatation procedure, a
self-expandable carotid stent was placed across the
stenosis. The residual stenotic segment was then post-
dilated using a 5- or 6-mm diameter balloon catheter
(Symmetry, Amiia, or Savvy) with the exception of two
cases. In the case of using a balloon device, the protective
balloon occlusion, the procedures for aspirating the debris
and balloon deflation were repeated in each step. The
balloon dilation was not performed more than twice, or for
longer than 10 seconds in duration. A completion
angiogram was obtained after removing the protection
device.
Diffusion Weighted Image Acquisition 
DWI was obtained using a 1.5 T MR imaging apparatus
(Signa Horizon or Signa CV/I; GE Medical Systems,
Milwaukee, WI) or a 3.0 T MR imaging apparatus (Intera
Achieva 3.0T; Philips Medical Systems, Best, Netherlands).
Besides DWI, the other sequences were obtained, which
included the axial spin echo T1 weighted image, the fast
spin echo T1 image, the fast spin echo T2 weighted image,
the FLAIR (fluid-attenuated inversion-recovery) image, the
perfusion image and the contrast enhanced spin echo T1
weighted image. DWI was acquired with the echo-planar
method. The TR/TE/NEX, field of view, the matrix and b-
values were 6500/97/1, 280 mm, 128 128, 0 and 1000
s/mm
2, respectively, for the 1.5 T MR apparatus, and
3421.3/60/1, 24 mm, 176 176, 0 and 1000 s/mm
2 for the
3.0 T MR apparatus, respectively. 
RESULTS
All the CAS procedures were technically successful.
Table 1 gives a list of the baseline characteristics of the
patients. Among several variables, only the degree of
contralateral carotid artery stenosis showed a significant
difference between the CAS-B and CAS-F groups (the
mean value was 37.2 vs. 19.0, respectively, p = 0.01). In
addition, there was a significant difference in the incidence
of severe stenosis (> 70%) or occlusion of the contralateral
carotid artery between the two groups (6 vs. 1; p = 0.04,
Pearson’s 
2 test). The mean time from the procedure to
the acquisition of the pre- and post-procedural DWI in the
CAS-B group was 2.3 and 1.2 days, respectively (range:
0 7 and 1 3 days, respectively), and 2.7 and 1.4 days,
respectively (range: 0 7 and 1 4, respectively) in the
CAS-F group. The differences between the two groups
were not significant (p = 0.59 and 0.12, respectively,
Kim et al.
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Table 1. Patients’ Characteristics 
Characteristics CAS-B (n=33) CAS-F (n=38) P-value
Age 68.1 7.9 66.4 8.6 0.42*
Gender (male) 29 (87.8) 31 (81.6) 0.46*
Degree of carotid artery stenosis
Ipsilateral (mean) 80.0 11.7 78.0 15.8 0.76*
Contralateral (mean) 37.2 33.1 19.0 25.9 0.01*
Presenting symptom
Cerebral infarction 13 (39.4%) 14 (36.8%) 0.84*
TIA or amaurosis fugax 10 (30.3%) 10 (26.3%)
Asymptomatic 10 (30.3%) 14 (36.8%)
Note. Continuous variable are expressed as the mean  standard 
deviation and categorical variable are expressed as n (%).
TIA = transient ischemic attack
* are calculated using independent t-tests or Mann-Whitney tests.
are calculated by Pearson 
2 tests.Mann-Whitney test).
A new HI on the post-procedural DWI was detected in
39.4% and 39.5% of the CAS-B patients and CAS-F
patients, respectively (Figs. 1, 2). The diameter of all new
high SI lesions on DWI was several millimeters and they
did not exceed 1 cm. There were no apparent major
arterial or territorial infarctions observed. The total
numbers of new ipsilateral and contralateral HIs were 55
and 24 in the CAS-B group, and 50 and 30 in the CAS-F
group. The mean numbers of ipsilateral, contralateral and
total new HIs were 1.67 (range: 0 31), 0.73 (range: 0 7),
and 2.39 (range: 0 32), respectively, in the CAS-B group,
and 1.32 (range: 0 16), 0.79 (range: 0 9), and 2.11
(range: 0 16), respectively, in the CAS-F group. Between
the two groups, there was a similar number of ipsilateral,
contralateral and total new HIs (p = 0.74, 0.65 and 0.96,
respectively, Mann-Whitney test) (Table 2). When the new
HIs were divided into cortical/juxta-cortical white matter,
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Fig. 1. A 72-year-old man who underwent protected carotid artery stenting with a balloon device.
A. Pre-stenting angiogram shows severe stenosis (86.3%) at the left internal carotid artery. 
B. A balloon device is deployed in the distal carotid artery (arrow). 
C. After carotid artery stenting, the lumen of the left internal carotid artery is successfully dilated.
D. No ischemic lesion is shown in bilateral cerebral hemispheres on the pre-stenting diffusion weighted MR imaging.
E. Multiple small new hyperintensities are shown on the post-stenting diffusion-weighted MR imaging. Note the new hyperintnesities are
distributed in not only the ipsilateral but also the contralateral cerebral hemisphere. However, no symptomatic neurological complications
occurred after carotid artery stenting.
DEdeep periventricular white matter and deep gray matter
according to their location, there were 64, 11 and four new
HIs in the CAS-B group, respectively, and 67, nine and
four in the CAS-F group, respectively. Although the
process and protective mechanism of the two devices were
different, there was no significant difference in the distribu-
tion of the new HIs between the two groups and almost all
infarctions appeared to result from a thromboembolism.
The mean numbers of ipsilateral, contralateral and total
new HIs for each of the three types of filter devices were
as follows: 0.43, 0.14 and 0.57 in the Filter Wire-EX
system, respectively, 0.87, 1.00 and 1.87 in the Filter
Wire-EZ system, respectively, and 3.38, 0.75 and 4.13 in
the Emboshield filter protection system, respectively.
There was no significant difference between the three
groups (p = 0.95, 0.83 and 0.87, respectively, Kruskal-
Wallis test) (Table 3). 
There were two cases of retinal artery embolisms and
Kim et al.
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Fig. 2. A 71-year-old man who underwent protected carotid artery stenting with a filter device.
A. Pre-stenting angiogram shows a severe string like stenosis of the left internal carotid artery. The post-stenotic distal internal carotid
artery is also narrow compared with the external carotid artery (pseudo-occlusion).
B. A filter device is deployed in the distal carotid artery (arrow).
C. After carotid artery stenting, the lumen of the left internal carotid artery is successfully dilated.
D. No ischemic lesion is shown in bilateral cerebral hemispheres on the pre-stenting diffusion weighted MR imaging.
E. Multiple small new hyperintensities are observed in the ipsilateral cerebral hemisphere on the post-stenting diffusion-weighted MR
images. However, no symptomatic neurological complications occurred after carotid artery stenting.
DEone case of hemiparesis occurred in the CAS-B group, and
one case of retinal artery embolism, one case of hemipare-
sis and one case of ataxia in the CAS-F group. In addition,
one case of hyperperfusion syndrome occurred in the
CAS-F group. The symptoms such as hemiparesis and
ataxia corresponded to the distribution of the new HIs on
DWI. The retinal embolism was demonstrated after the
procedure as a typical symptom and/or a loss of choroidal
blush immediately. For two of the three patients with
retinal embolisms, direct or indirect retinal artery
thrombolysis was performed and one retinal embolism was
successfully recanalized. Among the three patients with a
retinal embolism, two patients developed visual field
defects and one patient developed blindness. The overall
embolic complications such as retinal embolism, hemipare-
sis and ataxia were less frequent in the CAS-F group
(7.89%) than in the CAS-B group (9.09%). However,
there was no significant difference between the two groups
(p = 0.61, Fisher’s exact test). 
The mean number of risk factors was 1.30 in the CAS-B
group (range: 0 3) and 0.76 in the CAS-F (range: 0 2).
The number of risk factors was significantly higher in the
CAS-B group than in the CAS-F (p = 0.02, Mann-Whitney
test). Twenty-five CAS-Bs and 23 CAS-Fs were catego-
rized into a high-risk group with at least one risk factor,
and eight CAS-Bs and 15 CAS-Fs were categorized into a
low-risk group without any of the risk factors. In both the
high and low risk groups, there was a similar number of
ipsilateral, contralateral and total new HIs in the CAS-B
and the CAS-F groups (Table 4). In the high-risk group,
there were two cases of retinal artery embolisms and one
case of hemiparesis in the CAS-B, and one case of
hemiparesis in the CAS-F. In the low risk group, there
were no embolic complications in the CAS-B, and one case
of retinal artery embolism and one case of hemiparesis in
the CAS-F. In both the high and low risk groups, there was
a similar incidence of embolic complications in the CAS-B
and the CAS-F (p = 0.61 and 0.53, respectively, Fisher’s
exact test).
DISCUSSION
Carotid artery stenting has now been highlighted as an
alternative treatment to carotid endarterectomy (CEA)
because it is less invasive and it has a larger capability for
high-risk patients than CEA. According to the CAVATAS
(initial randomized multicenter clinical trial of Carotid and
Vertebral Transluminal Angioplasty Study), an endovascu-
lar treatment using stents or balloons showed similar
effectiveness in the treatment of carotid artery stenosis to
CEA (31). Although a previous study at our institution
showed a significantly higher rate of ischemic brain lesions
on DWI after unprotected CAS than after CEA, CAS
appeared to be a comparable method to conventional CEA
when considering the overall symptomatic complications
(32). The SAPPHIRE trial (Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy
trial), which was the first controlled randomized trial of
CAS using a protection device, suggested that CAS using
an embolic protection device was not inferior to CEA and
has a lower incidence of 30 day adverse clinical events
compared with CEA (33). Ouriel et al. reported a multicen-
ter feasibility trial of carotid artery stenting with and
without an embolus protection catheter, and concluded
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Table 3.  Comparison of the New High Signal Intensities
according to the Three Types of Distal Filter Devices
CAS-F EX  EZ  Emboshield 
(n = 38) (n = 7) (n = 23) (n = 8)
P-value
Ipsilateral 0.43 0.79 0.87 1.69 3.38 6.39 0.95*
Contralateral 0.14 0.38 1.00 2.54 0.75 1.49 0.83*
Total 0.57 0.79 1.87 2.93 4.13 7.06 0.87*
Note. Continuous variable are expressed as the mean  standard 
deviation.
* are calculated by Kruskal Wallis tests.
Table 4. Comparison of the New High Signal Intensities
between the CAS-B and CAS-F Groups according to
the Risk Categories
High Risk  CAS-B (n = 25) CAS-F (n = 23) P-value
Ipsilateral 2.08 6.18 1.91 4.07 0.87*
Contralateral 0.96 1.90 0.83 1.97 0.52*
Total 3.04 6.67 2.74 4.67 0.95*
Low risk CAS-B (n = 8) CAS-F (n = 15) P-value
Ipsilateral 0.38 1.06 0.40 0.91 0.83*
Contralateral 0.00 0.00 0.73 2.34 0.64*
Total 0.38 1.06 1.13 2.50 0.59*
Note. Continuous variable are expressed as means standard 
deviation. 
* are calculated by Mann-Whitney tests.
Table 2. Comparison of the New High Signal Intensities
between the CAS-B and CAS-F Groups 
CAS-B (n = 33) CAS-F (n = 38) P-value
Ipsilateral 1.67 5.4 1.32 3.3 0.74*
Contralateral 0.73 1.7 0.79 2.1 0.65*
Total 2.39 5.9 2.11 4.0 0.96*
Note. Continuous variable are expressed as the mean  standard 
deviation.
* are calculated by Mann-Whitney tests.that the use of an embolus protection device might reduce
the risk of postprocedural major ipsilateral strokes (34). 
The concept of cerebral protection during CAS was first
introduced through the modification of a protection device
that was originally used in saphenous vein graft interven-
tion, and the effectiveness of a cerebral protection device
was first mentioned in 1990 (35, 36). Three methods are
currently used for cerebral protection. These include distal
balloon devices, distal filter devices and proximal occlusion
catheters. Each device has its own advantages and
disadvantages. 
Any distal protection device, either a filter or balloon,
needs to pass through the stenotic portion before being
positioned in the distal internal carotid artery, and the
catheter passage itself might provoke distal embolization.
Minor movement of the inflated balloon or deployed filter
may also cause internal injury. Balloon devices are easier
to adapt to stenotic or tortuous vessels than filter devices.
However, balloon dilatation might cause a dissection or
spasm of the distal internal carotid artery. In addition,
patients with the incomplete development of the circle of
Willis may not tolerate any disruption in the internal
carotid artery flow (37). In this series, such intolerance was
encountered in two patients when the internal carotid
artery (ICA) flow was disrupted after balloon occlusion.
These patients were excluded from the study. After
balloon dilatation, the disrupted blood flow proceeds into
the external carotid artery, which may cause a retinal or
cerebral embolization through the external-internal carotid
or the external carotid-ophthalmic or the external carotid-
vertebral potential anastomotic channels (38, 39). In
contrast, filter devices do not completely disrupt the blood
flow. However, they cannot prevent the transport of
embolic particles smaller than the filter pore. Moreover,
the process of filter retrieval itself might cause distal
embolization. The proximal occlusion catheter does not
need to cross the stenotic lesion and can capture all particle
sizes. Unlike a distal balloon occlusion or filter device, the
proximal occlusion catheter can induce reversed flow from
the ICA and the external carotid artery (ECA) to the
common carotid artery (CCA) by occluding the CCA.
However, the proximal occlusion catheter can stop the
antegrade cerebral blood flow possibly resulting in intoler-
ance (40).
Among the three kinds of protection devices, the balloon
devices and the filter devices are in general use. The use of
a balloon device is now decreasing on account of its techni-
cal complexity. In contrast, the use of a filter device has
increased to the point that it now exceeds that of the
balloon device because the filter device is technically easier
for interventional neuroradiologists to handle than balloon
devices. However, the safety of the two different protec-
tion devices has not yet been fully tested. 
In this study, the incidence of new DWI lesions after
protected CAS was similar in the both groups (39.4% in
the CAS-B group and 39.5% in the CAS-F group). Among
Kim et al.
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Table 5. Several Case Series or Trials for Protected Carotid Artery Stenting: Characteristics and 30-day Outcomes
Year Author or Name Procedures 30-day  30-day 30-day Protection 
Stroke Death  MI Devices  Used
2002 Al-Mubarak 164 2 2 0 1, 2, 3
2002 Angelini 38 0 1 1 3
2002 Whitlow 75 0 0 0 2
2003 Cremonesi 442 5 0 0 1, 3, 4, 5, 6, 7
2003 Castellan 29 0 0 0 8, 9
2004 SAPPHIRE 159 9 11 4 3
2005 BEACH 747 32 11 6 4, 10
2005 Ouriel 85 3 3 0 3
2006 Hill 52 2 1 1 11
Note. MI = myocardial infarction
1NeuroShield (Mednova Inc., Galway, Ireland)
2GuardWire (Percusurge Inc., Sunnyville, CA)
3Angioguard (Cordis Inc., Miami, FL)
4FilterWire EX (Boston Scientific Corp. Natick, MA)
5Trap Filter (Microvena/EV3, Plymouth, MN)
6Percuserge (Medtronic Inc., Danvers, MA)
7Medicorp occlusive balloon (Medicorp Inc., Villers-les-Nancy, France)
8Angioguard (J & J Cordis Europe, Roden, The Netherlands)
9EPI Filter Wire EX (Boston Scientific Corp., Santa Clara, CA)
10FilterWire EZ (Boston Scientific Corp., Natick, MA)
11Interceptor Carotid Filter System (Medtronic Inc., Minneapolis, MN)these new DWI lesions, 30.4 % in the CAS-B group and
37.5 % in the CAS-F group were attributed to lesions
contralateral to the treated side. Embolic complications
such as retinal artery embolism, hemiparesis and ataxia,
occurred only in 7.89% and 9.09% of the CAS-F and
CAS-B group, respectively. Such a high incidence of so-
called silent ischemic lesions and a large proportion of new
ischemic lesions in the territory contralateral to the treated
side corresponded to the results of a previous study that
used two types of distal filter devices (12). Similar to their
assumption, besides crossing and angioplasty in the
targeted ICA, the handling at the level of the aortic arch or
the common carotid artery before placing the protection
device and diagnostic angiography at the contralateral ICA
appeared to be the cause of the high incidence of new DWI
lesions. Collateral flow through the anterior communicat-
ing artery also might be one of causative factors for a
contralateral ischemic lesion.
Although the numbers of risk factors were significantly
higher in the CAS-B group, the number of ipsilateral,
contralateral and total new HIs were similar in both the
high and low risk groups. In addition, the incidence of
embolic complications such as a retinal artery embolism,
hemiparesis and ataxia were similar in both risk groups in
the CAS-B and the CAS-F groups.
There have been several comparative studies on the
efficacy of the various protection devices. Zahn et al.
compared the effectiveness of the balloon device in 176
patients and the filter device in 553 patients, and
concluded that the occurrence of in-hospital death or
stroke was similar in the two groups (2.3% vs. 1.8%,
respectively) (41). Muller-Hulsbeck et al. compared the
efficacy of four types of cerebral protection devices using
an in vitro model and concluded that the NeuroShield filter
and the FileterWire EX captured the highest percentage of
human emboli (42).
There also have been several case series or trials on
protected CAS using either a filter or balloon device. Table
5 summarizes the characteristics and 30-day outcomes of
these studies (33, 34, 43 49). 
This study had some limitations. First, the proportion of
the four stent types was not identical in the CAS-B and
CAS-F groups. Therefore, besides the different types of
protection devices, the influence of the different stent
types on the occurrence of new HI could not be completely
excluded. Second, during the course of study, the balloon
catheters available tended to decrease in diameter and
improve in quality. Therefore, such improvements might
also have influenced the results. Third, there was a signifi-
cant difference in degree of contralateral carotid artery
stenosis between the CAS-B and CAS-F groups (the mean
value was 37.2 vs. 19.0, respectively, p = 0.01). Therefore,
the effect of such a difference on the results also cannot be
ignored.
In conclusion, the overall occurrence of new embolic
cerebral lesions detected on DWI was higher than
expected. The types of distal protection devices, i.e.
balloon or filter, did not significantly affect the occurrence
of cerebral embolization. The operator’s decision after
considering the individual strengths and weaknesses of the
various protection devices that are appropriate to different
circumstances appears to be important. 
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